1. Home
  2. TSLX vs COGT Comparison

TSLX vs COGT Comparison

Compare TSLX & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSLX
  • COGT
  • Stock Information
  • Founded
  • TSLX 2010
  • COGT 2014
  • Country
  • TSLX United States
  • COGT United States
  • Employees
  • TSLX N/A
  • COGT N/A
  • Industry
  • TSLX Investment Managers
  • COGT Biotechnology: Pharmaceutical Preparations
  • Sector
  • TSLX Finance
  • COGT Health Care
  • Exchange
  • TSLX Nasdaq
  • COGT Nasdaq
  • Market Cap
  • TSLX 2.2B
  • COGT 2.3B
  • IPO Year
  • TSLX 2014
  • COGT 2018
  • Fundamental
  • Price
  • TSLX $21.08
  • COGT $14.70
  • Analyst Decision
  • TSLX Buy
  • COGT Strong Buy
  • Analyst Count
  • TSLX 9
  • COGT 12
  • Target Price
  • TSLX $23.44
  • COGT $22.00
  • AVG Volume (30 Days)
  • TSLX 578.9K
  • COGT 2.5M
  • Earning Date
  • TSLX 11-04-2025
  • COGT 10-31-2025
  • Dividend Yield
  • TSLX 9.64%
  • COGT N/A
  • EPS Growth
  • TSLX N/A
  • COGT N/A
  • EPS
  • TSLX 2.04
  • COGT N/A
  • Revenue
  • TSLX $464,512,000.00
  • COGT N/A
  • Revenue This Year
  • TSLX N/A
  • COGT N/A
  • Revenue Next Year
  • TSLX N/A
  • COGT N/A
  • P/E Ratio
  • TSLX $10.36
  • COGT N/A
  • Revenue Growth
  • TSLX N/A
  • COGT N/A
  • 52 Week Low
  • TSLX $18.58
  • COGT $3.72
  • 52 Week High
  • TSLX $25.17
  • COGT $17.15
  • Technical
  • Relative Strength Index (RSI)
  • TSLX 33.08
  • COGT 46.67
  • Support Level
  • TSLX $22.36
  • COGT $13.79
  • Resistance Level
  • TSLX $23.19
  • COGT $16.76
  • Average True Range (ATR)
  • TSLX 0.44
  • COGT 0.95
  • MACD
  • TSLX -0.03
  • COGT -0.27
  • Stochastic Oscillator
  • TSLX 0.47
  • COGT 28.72

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: